Pharmacogenomics: Genentech, OSI and Other Pharmas Personalize Medicine
In fact, it is the other way around - it is testing to determine whether you fit the drug. Pharmacogenomics is a combination of genetic testing (genomics) with drugs (pharmacology).
Right now, most drugs are a "one size fits all" medication. A drug is formulated and tested in a population and some respond really well while others may suffer adverse events. If there are more benefits than risks, generally the drug gets approved. Once out in the general population, that profile will repeat itself - many will benefit and many will not.
However, a growing number of drugs come with a more analytic approach to the patient. Genetic testing may predict whether a patient is a good candidate for treatment with a particular medication - the "personalized" part of personalized medicine. Good examples of drugs whereby genetic testing makes their use more effective include Herceptin (Genentech: (DNA)) and Tarceva (OSI Pharmaceuticals: (OSIP)) and even anti-virals used to fight HIV, where genetic testing can tell you if the virus you harbor is resistant to certain drugs. And there are many benefits in the future that can be realized in the broader application of pharmacogenomics.
The FDA has outlined the promise of pharmacogenomics in many public statements, including the so-called "critical path initiative" and there are several backgrounders and primers on pharmacogenomics on the FDA Web site.
But right now on the Hill, there is a bill introduced before Congress that is key for any real future for personalized medicine called S. 358 - the Genetic Information Nondiscrmination Act of 2007, introduced by Senator Olympia Snow (R-Maine), which would prohibit discrimination in employment and health insurance based on genetic information.
Imagine that there was a promising therapy for you, but in order to find out which one best suited you, you underwent genetic testing. That testing will reveal information about you that a health insurer or employer might find unappealing. You are then faced with a choice - do you take the test or do you forgo the therapy in the interest of preserving your job and your health insurance? Key to the future of personalized medicine is an umbrella of protection that makes sure that it's a choice you don't have to make.
This is but one of many examples of how public policy can directly promote or impede medical progress. Let's hope this one ends up in the right place. You can track the progress by using GovTrack in the column at the right on the blog (EyeOnFDA.com).
Cheers!
Source: EyeOnFDA.com
RELATED READING:
Potential Trouble Ahead For Big Biotechs Cancer Drug, but not Drug Company, Praised by Networks Johnson & Johnson and Amgen: The Drug Marketing Blues
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
ETFs In Focus
-
Editor's Picks
-
Most Popular
- ETF Insights: The New Hard Assets Producers ETF
- Why Airline Stocks Are So Often Bad Investments
- The Chinese Oil Problem
- Wildfires, Financial Crises, and Type Conversions in Markets
- The Most Important Fact To Know About Oil Investing
- New Currency ETN from Barclays
- Full list of Editor's Picks »
- Chesapeake Energy Called the Market's Bluff »
- Three Reasons the Solar Sell-off May Be in the Early Innings »
- Five Reason Steve Ballmer Thinks Apple's a Buy »
- WaMu: Speculative Value Play »
- Wall Street Breakfast: Must-Know News »
- What's in Store for the Fertilizer Industry? »
- Wall Street Breakfast: Must-Know News »
- Apple to Reveal Mysterious Product Transition on September 9th »
- Wall Street Breakfast: Must-Know News »
- Residential Real Estate: How Much More Pain? »
- Precious Metals Manipulation: Lawyers Prepare for Battle »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- Things Aren't Good - Fast Money Recap (9/4/08)
- ETFs That Help You Sleep Better at Night
- ETF Update: Alternative Energy and the Power Grid
- ETF Update: Healthcare Has a Heartbeat; A Good Time for Muni-Bond ETFs?
- Hansen Natural: Amazing Growth Stock Now Attractive to Value Investors
- MasterCard: Driven by Global Growth
- U-turn: Uranium Begins Recovery Phase
- Guru Picks: Five Blue Chips
- Have European Stocks Pulled Back Too Far?
- Time to Rethink Our View of Private Health Insurers?
- Full list of Long Ideas »
- Short Interest Rising in Tesoro; Shorts Covering Airline Positions
- Harbinger Capital: Cut Short
- Not Much Meat on Pilgrim's Pride's Bones
- Salesforce.com: Demystifying the Force
- Should We Listen to Boone Pickens on Oil?
- Energy Conversion Devices: Ridiculously High Valuation
- Three Reasons the Solar Sell-off May Be in the Early Innings
- Is the Market Rolling Over?
- Solar and Oil, Part Deux
- Financial vs. International ETFs: Which Bear is Grizzlier?
- Full list of Short Ideas »
- Cramer Sees the Light - Cramer's Mad Money (9/4/08)
- Keep Buying Big Brown - Cramer's Lightning Round (9/4/08)
- Don't Buy These Bonds - Cramer's Stop Trading! (9/4/08)
- Loss of Integrity - Cramer's Mad Money Recap (9/3/08)
- Not Off the RIMM - Cramer's Lightning Round (9/3/08)
- Unbelievable Moves - Cramer's Stop Trading! (9/3/08)
- The Rally was the Real Deal - Cramer's Mad Money (9/2/08)
- Crushed Unnecessarily - Cramer's Lightning Round (9/2/08)
- A Chance to Sell - Cramer's Stop Trading! (9/2/08)
- Faith Doesn't Cut It - Cramer's Mad Money (8/29/08)
- Full list of Cramers Picks »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »


